perhaps the turning point lies precisely in the PR

perhaps the turning point lies precisely in the PR of 27 April.
Moscato tells us that they will provide data, research results, production methods to the Chinese partners, so that they can present Ind in China.
Under the agreement, the Chinese partners are responsible for the development and approval of the li-key vaccine at the Chinese equivalent of the fda. "All clinical trials will be conducted according to the guidelines of the International Council on Harmonization (ICH), so that the data can be used for submission to the FDA, EMEA and other international regulatory agencies." Imho, Gnbt is in a vicious circle: it cannot quote Ngio until there are concrete data that can arouse interest and increase its value, it cannot obtain these data because there is a lack of funds that paradoxically it could obtain by listing Ngio.
Through this latest agreement, it "delegates" the Chinese partners the burden of preparing Ind and future phase 1 and 2 studies, in exchange for the vaccine rights for China (the rest of the world remains for Generex); at the same time, it can exploit the work of certainly the wealthiest and fastest Chinese partners, and use the same data for the presentation of Ind and furure studies at Fda and also Emea...